Program
AZD4248
A development code.
Its studies are mostly in Renal Insufficiency, Chronic, led by AstraZeneca.
Furthest: phase 1, since Jun 9, 20251 company-led study, 1 open or runningNext primary completion: Jan 29, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 1since Jun 9, 2025 | Jun 9, 2025 | Jan 29, 2027phase 1 · NCT07024823 |
- Named in AstraZeneca’s own pipeline as
AZD4248
, phase 1, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2025First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT07024823 · 192 planned · United States
Ahead
- Jan 29, 2027Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07024823
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07024823Renal Insufficiency, Chronic · United States | 1 | Recruiting | Jan 29, 2027 | 192 |
How it is read
Names in the registry
- “AZD4248”, 2 entries
Codes read as this program: AZD4248.
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.